ExpreS2ion Biotech: Pioneering the Future of Vaccines at Key Industry Events
November 5, 2024, 5:19 am
Location: Denmark, Capital Region of Denmark, Hørsholm Municipality
Employees: 11-50
Founded date: 2010
Total raised: $5.43M
ExpreS2ion Biotech is making waves in the biotechnology sector. The company is gearing up for a series of high-profile presentations and events that could reshape its future. With a focus on innovative vaccine development, ExpreS2ion is positioning itself as a leader in the fight against infectious diseases.
The BioStock Life Science Summit is on the horizon. Scheduled for November 20-21 in Lund, Sweden, this event is a magnet for industry leaders and investors. ExpreS2ion's CEO, Bent U. Frandsen, will take the stage on November 21 at 10:50 AM. This is not just another presentation; it’s a chance to connect innovation with capital. The summit serves as a platform for small to medium-sized Nordic companies to showcase their potential.
The setting is intimate yet powerful. Investors and partners gather to explore the latest advancements in life sciences. For ExpreS2ion, this is a golden opportunity. The company aims to attract attention and funding for its groundbreaking technology. The event will be filmed and shared online, amplifying its reach.
But the BioStock Summit is just one stop on ExpreS2ion's busy calendar. The company is also participating in several other key events. From November 4-6, ExpreS2ion will be at BIO-Europe in Stockholm. This is one of the largest biotech partnering events in Europe. Here, Frandsen will represent the company, aiming to forge new partnerships and collaborations.
Next, ExpreS2ion heads to Barcelona for the Protein & Antibody Engineering Summit Europe from November 5-7. This event is the largest of its kind in Europe, focusing on protein and antibody engineering. It includes a dedicated stream on oncology, highlighting the growing importance of cancer research. Max Soegaard, ExpreS2ion's Senior Vice President of R&D and Technology, will be on hand to discuss the company’s advancements.
On November 14, ExpreS2ion will hold a virtual presentation to discuss its third-quarter results. This is a critical moment for investors. Frandsen and CFO Keith Alexander will provide insights into the company’s financial health and future prospects. Investors will have the chance to ask questions, making this an interactive session.
Finally, on November 18, ExpreS2ion will participate in the LSX Investival Showcase in London. This event is a networking hub for biotech, healthtech, and medtech companies. CFO Alexander will represent ExpreS2ion, seeking to connect with potential investors and partners.
ExpreS2ion’s strategy is clear: increase visibility and attract investment. The company is on a mission to revolutionize vaccine development. Its proprietary technology platform, ExpreS2™, is a game-changer. This platform allows for the rapid and efficient production of vaccine components. It has been validated in human clinical Phase III trials, underscoring its reliability.
The platform also features GlycoX-S2™, which enhances immunogenicity and pharmacokinetics. This means better vaccines that work more effectively in the human body. Since its inception in 2010, ExpreS2ion has produced over 500 proteins and virus-like particles (VLPs). Collaborations with leading research institutions have bolstered its credibility.
ExpreS2ion is not just about technology; it’s about impact. The company aims to develop life-saving vaccines that improve global health. Its partnership with AdaptVac ApS, in which it holds a 34% stake, is a testament to its commitment to innovation. Together, they are working on novel VLP-based vaccines.
The landscape of biotechnology is ever-evolving. Companies like ExpreS2ion are at the forefront of this change. Their participation in key events highlights their ambition and drive. The upcoming presentations are not just about showcasing technology; they are about building relationships.
Investors are keen to support companies that demonstrate potential. ExpreS2ion’s innovative approach to vaccine development positions it well in a competitive market. The company’s focus on collaboration and partnership is a smart move. It opens doors to new opportunities and resources.
As the world grapples with health challenges, the need for effective vaccines has never been greater. ExpreS2ion is rising to the occasion. Its technology could play a crucial role in addressing global health issues.
In conclusion, ExpreS2ion Biotech is poised for a breakthrough. With a packed schedule of events and a strong technological foundation, the company is ready to make its mark. The upcoming presentations are not just milestones; they are stepping stones toward a healthier future. The world will be watching as ExpreS2ion takes center stage in the biotechnology arena.
The BioStock Life Science Summit is on the horizon. Scheduled for November 20-21 in Lund, Sweden, this event is a magnet for industry leaders and investors. ExpreS2ion's CEO, Bent U. Frandsen, will take the stage on November 21 at 10:50 AM. This is not just another presentation; it’s a chance to connect innovation with capital. The summit serves as a platform for small to medium-sized Nordic companies to showcase their potential.
The setting is intimate yet powerful. Investors and partners gather to explore the latest advancements in life sciences. For ExpreS2ion, this is a golden opportunity. The company aims to attract attention and funding for its groundbreaking technology. The event will be filmed and shared online, amplifying its reach.
But the BioStock Summit is just one stop on ExpreS2ion's busy calendar. The company is also participating in several other key events. From November 4-6, ExpreS2ion will be at BIO-Europe in Stockholm. This is one of the largest biotech partnering events in Europe. Here, Frandsen will represent the company, aiming to forge new partnerships and collaborations.
Next, ExpreS2ion heads to Barcelona for the Protein & Antibody Engineering Summit Europe from November 5-7. This event is the largest of its kind in Europe, focusing on protein and antibody engineering. It includes a dedicated stream on oncology, highlighting the growing importance of cancer research. Max Soegaard, ExpreS2ion's Senior Vice President of R&D and Technology, will be on hand to discuss the company’s advancements.
On November 14, ExpreS2ion will hold a virtual presentation to discuss its third-quarter results. This is a critical moment for investors. Frandsen and CFO Keith Alexander will provide insights into the company’s financial health and future prospects. Investors will have the chance to ask questions, making this an interactive session.
Finally, on November 18, ExpreS2ion will participate in the LSX Investival Showcase in London. This event is a networking hub for biotech, healthtech, and medtech companies. CFO Alexander will represent ExpreS2ion, seeking to connect with potential investors and partners.
ExpreS2ion’s strategy is clear: increase visibility and attract investment. The company is on a mission to revolutionize vaccine development. Its proprietary technology platform, ExpreS2™, is a game-changer. This platform allows for the rapid and efficient production of vaccine components. It has been validated in human clinical Phase III trials, underscoring its reliability.
The platform also features GlycoX-S2™, which enhances immunogenicity and pharmacokinetics. This means better vaccines that work more effectively in the human body. Since its inception in 2010, ExpreS2ion has produced over 500 proteins and virus-like particles (VLPs). Collaborations with leading research institutions have bolstered its credibility.
ExpreS2ion is not just about technology; it’s about impact. The company aims to develop life-saving vaccines that improve global health. Its partnership with AdaptVac ApS, in which it holds a 34% stake, is a testament to its commitment to innovation. Together, they are working on novel VLP-based vaccines.
The landscape of biotechnology is ever-evolving. Companies like ExpreS2ion are at the forefront of this change. Their participation in key events highlights their ambition and drive. The upcoming presentations are not just about showcasing technology; they are about building relationships.
Investors are keen to support companies that demonstrate potential. ExpreS2ion’s innovative approach to vaccine development positions it well in a competitive market. The company’s focus on collaboration and partnership is a smart move. It opens doors to new opportunities and resources.
As the world grapples with health challenges, the need for effective vaccines has never been greater. ExpreS2ion is rising to the occasion. Its technology could play a crucial role in addressing global health issues.
In conclusion, ExpreS2ion Biotech is poised for a breakthrough. With a packed schedule of events and a strong technological foundation, the company is ready to make its mark. The upcoming presentations are not just milestones; they are stepping stones toward a healthier future. The world will be watching as ExpreS2ion takes center stage in the biotechnology arena.